Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Replay Bio

News headline image
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
From Replay Bio
Via GlobeNewswire
News headline image
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
From Replay Bio
Via GlobeNewswire
News headline image
Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy®
From Replay Bio
Via GlobeNewswire
News headline image
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens
From Replay Bio
Via GlobeNewswire
News headline image
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
From Replay Bio
Via GlobeNewswire
News headline image
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma
From Replay Bio
Via GlobeNewswire
News headline image
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma
From Replay Bio
Via GlobeNewswire
News headline image
Cristian Massacesi, M.D., Appointed to Replay Board of Directors
From Replay Bio
Via GlobeNewswire
News headline image
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
From Replay Bio
Via GlobeNewswire
News headline image
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
From Replay Bio
Via GlobeNewswire
News headline image
Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology
From Replay Bio
Via GlobeNewswire
News headline image
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
From Replay Bio
Via GlobeNewswire
News headline image
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases
From Replay Bio
Via GlobeNewswire
News headline image
Replay launches its first HSV gene therapy company, Eudora, focused on retinal eye disease
From Replay Bio
Via GlobeNewswire
News headline image
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts
From Replay Bio
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.